Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 148465-45-6
2. Cid 17397714
3. Zinc9497828
4. Akos016487279
5. Z164754034
6. 923916-82-9
| Molecular Weight | 308.3 g/mol |
|---|---|
| Molecular Formula | C18H16N2O3 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 308.11609238 g/mol |
| Monoisotopic Mass | 308.11609238 g/mol |
| Topological Polar Surface Area | 64.4 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 385 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
NDC API
NDC Package Code : 66039-854
Start Marketing Date : 2013-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17359-8750
Start Marketing Date : 2023-12-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jaguar Health Submits Breast Cancer Therapy Diarrhea Impact Study Abstract
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2024
Details:
Mytesi (crofelemer) is a plant-based drug extracted & purified from the red bark sap. It is being developed for relief and treatment of prophylaxis of diarrhea in cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jaguar Health Reports Improvement in Breast Cancer Patients in Phase 3 OnTarget Trial
Details : Mytesi (crofelemer) is a plant-based drug extracted & purified from the red bark sap. It is being developed for relief and treatment of prophylaxis of diarrhea in cancer patients.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Details:
Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jaguar Health to Report Phase 3 Trial Results for Crofelemer on or Before July 23, 2024
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2024
Details:
Crofelemer is a novel, oral plant-based medicine purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree in the Amazon Rainforest.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jaguar Health’s Crofelemer Trial Shows Positive Results for Functional Diarrhea
Details : Crofelemer is a novel, oral plant-based medicine purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree in the Amazon Rainforest.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2024
Details:
The company submitted a CTA to the Italian and German health authorities to initiate a phase 2 trial of Mytesi (crofelemer) for the treatment of short bowel syndrome with intestinal failure in adults.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Jaguar Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Jaguar Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Jaguar Submits Clinical Trial Applications for Crofelemer in Rare Diseases
Details : The company submitted a CTA to the Italian and German health authorities to initiate a phase 2 trial of Mytesi (crofelemer) for the treatment of short bowel syndrome with intestinal failure in adults.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2024
Details:
GEN will manufacture Mytesi (crofelemer) and market it for HIV-related diarrhea in Turkey and neighboring countries after receiving regulatory approval.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: GEN
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : GEN
Deal Size : Undisclosed
Deal Type : Licensing Agreement
GEN to Commercialize Jaguar’s Crofelemer in Turkey and Invest $2 Million in Stock
Details : GEN will manufacture Mytesi (crofelemer) and market it for HIV-related diarrhea in Turkey and neighboring countries after receiving regulatory approval.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 20, 2024
Details:
Crofelemer is a plant-based drug extracted from red bark sap, being developed for treating moderate-to-severe diarrhea from various infections, including Vibrio cholerae.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jaguar Submits Orphan Drug Designation Application for Crofelemer
Details : Crofelemer is a plant-based drug extracted from red bark sap, being developed for treating moderate-to-severe diarrhea from various infections, including Vibrio cholerae.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 12, 2024
Details:
Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Details:
Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Brand Name: Mytesi
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Quadri Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Quadri Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 02, 2023
Details:
Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Brand Name: Mytesi
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
